Skip to main content
World Health Organization Approves CBD

What Does the World Health Organization Say About CBD?

Today we want to cover some recent exciting news for all fans of CBD, as well as for the health and well-being of the planet in general. The World Health Organization (WHO) recently announced that it deems CBD to be safe and recommends that it be exempt from drugs scheduling. 

U.S. law relegates CBD concentrates under Schedule 1 narcotics, the label reserved for the most dangerous drugs with a high potential for abuse and no medicinal value. CBD, of course, is neither dangerous nor devoid of medicinal value. CBD has no intoxicating effects but is thought to provide relief for a variety of ailments including arthritis, chronic pain, and seizures.

This decision by the WHO, the health division of the UN, is welcome news for many who already use CBD as a dietary supplement or for treatment of illness, as well as for the industry as a whole. The WHO committee based their ruling on an internal study on the medical benefits of CBD. In addition to ruling that CBD is indeed effective, the study concluded that there was no addiction risk involved with the use of CBD.

“There is increased interest from Member States in the use of cannabis for medical indications including for palliative care,” the WHO’s Expert Committee on Drug Dependence wrote in their medical ruling on CBD. “Responding to that interest and increase in use, WHO has in recent years gathered more robust scientific evidence on therapeutic use and side effects of cannabis and cannabis components.”

“ECDD did an initial review of a cannabis compound called cannabidiol (CBD),” the committee noted. “Recent evidence from animal and human studies shows that its use could have some therapeutic value for seizures due to epilepsy and related conditions... Current evidence also shows that cannabidiol is not likely to be abused or create dependence as for other cannabinoids (such as Tetrahydrocannabinol (THC), for instance). The ECDD therefore concluded that current information does not justify scheduling of cannabidiol.”